Nafsika Georgopapadakou, PhD, Vice President, Research at NovaBay Pharmaceuticals, Inc., (AMEX: NBY), was interviewed by television stations across the country this week to discuss the growing problem of methicillin-resistant Staphylococcus aureus (MRSA), the rise in “super bugs” (multi-drug-resistant pathogens) and steps that can be taken to prevent systemic bacterial infections. The interviews were part of a broad patient education initiative undertaken by NovaBay to create not only awareness of this looming threat, but also to promote new thinking and approaches to treating “superbugs.”
Television stations that interviewed Dr. Georgopapadakou included WIAT-TV (CBS) in Birmingham, AL, KAL-TV (NBC) in Salt Lake City, UT and KOTV-TV (CBS) in Tulsa, OK. Radio interviews included WTNJ-FM in Albuquerque, NM, and WNTQ-FM in Syracuse, NY.
During the interviews, Dr. Georgopapadakou discussed how broad antibiotic use and misuse may have contributed to the rise of MRSA and other super bugs and how the emergence of multi-drug-resistant bacteria have spurred new thinking on how to use still-active antibiotics. Among approaches described by Dr. Georgopapadakou to help preserve the current arsenal of antibiotics was using Aganocide® compounds to eradicate super bugs at the point of entry. She highlighted Aganocides’ broad-spectrum of activity against MRSA, vancomycin-resistant Enterococcus (VRE) and other potentially deadly bacteria by safely eliminating them from the eyes, nose ears and surgical-site infections before they have a chance to become systemic.
Novabay’s Aganocide® compounds work by mimicking our own natural defense molecules against infection and were created from stable analogs of the most effective and rapidly-acting molecules that function within our own bodies. Their lead Aganocide® compound, NVC-422, kills bacteria in minutes even at low concentrations.
Journalists or shareholders interested in receiving a CD of aired interviews may submit a request to email@example.com.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. The company also has a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound-care applications.
NovaBay™, AgaDerm™ Aganocide®, AgaNase™, and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
NovaBay Pharmaceuticals Contacts
Head of Investor Relations
The Investor Relations Group
Adam Holdsworth / Erica Ruderman / Brett Foley
Janet Vasquez / Laura Colontrelle